COVID-19 vaccine by NovaVax was approved for domestic items on the 12th. At the final inspection committee held on the same day, experts judged that the Novavax vaccine had a sufficient effect on preventing COVID-19.

The MFDS announced on the 12th that SK Bioscience has decided to approve the product on the condition that it submits a final report on the clinical trial results for the COVID-19 vaccine Nuvaxovid PFS, which has applied for approval for manufacturing and sales items. Nuvaxovid PFS is a gene recombinant COVID-19 vaccine developed by Novavax in the U.S. and manufactured by SK Bioscience in Korea from undiluted to complete. The main active ingredient is the same as a vaccine (10 vials packed